DexCom, Inc. (NASDAQ:DXCM) COO Jacob Steven Leach Sells 2,634 Shares

DexCom, Inc. (NASDAQ:DXCM) COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

DexCom Trading Up 1.4 %

DexCom stock opened at $87.62 on Friday. The stock has a 50-day moving average price of $80.22 and a 200 day moving average price of $76.59. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The stock has a market cap of $34.22 billion, a PE ratio of 52.47, a P/E/G ratio of 2.23 and a beta of 1.12. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Institutional Investors Weigh In On DexCom

Several hedge funds have recently modified their holdings of DXCM. Blue Whale Capital LLP boosted its position in DexCom by 91.9% during the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after acquiring an additional 113,000 shares during the last quarter. Taylor Frigon Capital Management LLC lifted its stake in shares of DexCom by 51.6% during the 3rd quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after purchasing an additional 11,075 shares during the period. Brooktree Capital Management acquired a new stake in shares of DexCom during the third quarter worth $683,000. National Pension Service grew its position in shares of DexCom by 4.1% in the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock valued at $63,671,000 after purchasing an additional 37,363 shares during the period. Finally, Intact Investment Management Inc. acquired a new position in DexCom in the third quarter valued at $650,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on DXCM. Wells Fargo & Company raised their price target on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. JPMorgan Chase & Co. increased their price target on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Royal Bank of Canada decreased their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Finally, Citigroup increased their target price on shares of DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus target price of $99.29.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.